Pelvic inflammatory disease

Navigating Birth Control: Expert Advice from Dr. Bana Kashani, OB-GYN

Retrieved on: 
Friday, March 29, 2024
Women, Other Communications, Baby, Maternity, Communications, Practice Management, Family, Health, Consumer, General Health, Birth, Pregnancy, Infertility, Q&A, Intrauterine device, Condom, Menstrual cycle, Sterilization, IUD, Ovulation, Research, Fertility, Pelvic inflammatory disease, Hormonal contraception, Tubing (recreation), STI, Woman, USB On-The-Go, Birth control

In a rapidly evolving landscape of reproductive health, navigating the variety of birth control options can be overwhelming.

Key Points: 
  • In a rapidly evolving landscape of reproductive health, navigating the variety of birth control options can be overwhelming.
  • “When choosing a birth control method, it's essential to consider factors such as efficacy, convenience, side effects, and personal preferences.
  • Dr. Kashani sheds light on various birth control methods in the following Q&A:
    What are the different types of birth control methods available?
  • There is limited evidence to suggest that using birth control methods for an extended period negatively impacts fertility.

Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections

Retrieved on: 
Tuesday, January 16, 2024
Development, Agreement, Patient, Infection, Ceftriaxone, Infertility, Social work, Science, Gonorrhea, STI, Administration, Pelvic inflammatory disease, Vaccination, Bill, Risk, Education, Bacteria, Neisseria gonorrhoeae, Disease, BMBF, Doctor of Philosophy, HIV, Human services, Vaccine, Chronic pain, DHSC, OMV

The Neisseria gonorrhoeae bacterium causes gonorrhea, the second most reported bacterial STI.

Key Points: 
  • The Neisseria gonorrhoeae bacterium causes gonorrhea, the second most reported bacterial STI.
  • Patients with gonorrhea can face serious health effects, including pelvic inflammatory disease, chronic pain, infertility, and an increased risk of contracting HIV.
  • Through the tailored gonococcal antigens on the surface of the meningococcal OMV, Intravacc anticipates a significant enhancement in the vaccine candidate’s efficacy against gonorrhea.
  • “This CARB-X project allows us to combine our science and OMV expertise for the development of a vaccine against gonorrhea infections.

Aspira Women’s Health Announces Dr. Jody Berry as New Chief Scientific Officer

Retrieved on: 
Monday, September 11, 2023
Department of Medical Microbiology (Schering AG), Abstract, Pelvic inflammatory disease, Bachelor of Science, University, Apotex, Medical microbiology, HIV, Cangene, HIV-1, Head, Monoclonal antibody, Public Health Agency of Canada, COVID-19, Woman, CIHR, Infection, Research, Lehigh University, American Biological Safety Association, National Microbiology Laboratory, University of Manitoba, Government, Immunochemistry, Chlamydia trachomatis, Philosophy, Outline, Gynaecology, Blood, Scripps Research, Protein engineering, R, Public Health Agency, G.H. Raisoni Department of Microbiology and Biotechnology, University Arena (Western Michigan University), Vaccine, Science, Chlamydia, Molecular biology, Aspira

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.

Key Points: 
  • AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer.
  • Dr. Berry is a seasoned scientific leader with over two decades of commercial, government and academic experience.
  • Jody is a dynamic leader with decades of experience launching disruptive products and building effective research and development teams,” said Nicole Sandford, Chief Executive Officer of Aspira.
  • Dr. Berry is author or co-author on over 100 peer-reviewed published journal articles, abstracts, scientific posters, and monographs.

Microbix Presents Results of STI Test Controls at ASM Microbe

Retrieved on: 
Tuesday, June 13, 2023
Pelvic inflammatory disease, STI, Infection, QAP, Infertility, Urethritis, AMR, RUO, Buffer, Mycoplasma genitalium, OTCQX, IVD, TSX, Poster, Cervicitis, American Society for Microbiology, Society, Vaccine, MGEN

At ASM Microbe, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.

Key Points: 
  • At ASM Microbe, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.
  • Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and nucleic acid (i.e., “PCR”) tests and their workflows.
  • Using innovative and proprietary methods, Microbix created and manufactured such materials – including for five AMR variants of Mgen.
  • Formatted onto COPAN® FLOQSwabs®, the resulting Microbix QAPs were then used to validate and support novel tests for AMR detection, namely the SpeeDx Pty.

Gonorrhoea and syphilis diagnoses are at their highest in decades – here's what you need to know about these STIs

Retrieved on: 
Saturday, June 10, 2023
Infection, Vagina, UK Health Security Agency, Pelvic inflammatory disease, Neisseria gonorrhoeae, Penis, STI, Syphilis, Deafness, Fever, Urethra, Congenital syphilis, Skin, Incontinence, Woman, Paratriathlon, Prostate, Abdominal pain, DSM-IV codes, Partner (business rank), Gonorrhea, Pain, Treponema pallidum, Man, Dementia, Time, Vaginal discharge, Risk, Child, Chronic pain, Security agency, Ulcer, Stillbirth, Chlamydia, Water, Ageing, Pregnancy, Diagnosis, Condom, Disease, Pharmaceutical industry, Birth control, Antibiotics, Treponema

Shockingly, gonorrhoea rates are the highest they have been since records began in 1918.

Key Points: 
  • Shockingly, gonorrhoea rates are the highest they have been since records began in 1918.
  • Gonorrhoea has increased from 71,133 diagnoses per year before the pandemic to 82,592 in 2022.
  • Syphilis, which in the early 2000s was almost non-existent in the UK, has increased to 8,692 diagnoses in 2022.

What symptoms do they cause?

    • In women symptoms can be less obvious, but include a watery, green, yellow or sometimes bloodstained vaginal discharge, and pain when urinating.
    • Symptoms include fever and abdominal pain.
    • For this reason, it’s essential to get diagnosed and treated if you’re experiencing any symptoms.
    • The disease now enters a latent phase where it stays in the body while showing no symptoms.
    • This causes a range of symptoms which were dreaded in the years before effective treatment – including skin and bone disfigurations, nerve pain, heart problems, deafness, blindness, dementia and other neurological symptoms such as difficulty walking and incontinence.

Why have rates increased?

    • It’s not entirely clear why rates of syphilis and gonorrhoea have increased so rapidly in the UK.
    • Data shows that rates of gonorrhoea in particular are sensitive to social and political change, including changes to funding for sexual health services.

What can I do to protect myself?

    • If you have a symptom you’re worried about, get it checked.
    • Self-test kits for gonorrhoea and syphilis are available online in some areas or you can go to a sexual health clinic if you prefer.

Myovant Sciences and Evidation Announce Survey Results of Unseen Burdens at Work and School of Individuals with Endometriosis and/or Uterine Fibroids

Retrieved on: 
Wednesday, May 17, 2023
Wearables, Mobile Technology, Technology, Women, Health Technology, Software, Consumer, Health, Data Management, Science, Other Science, Endometriosis, Pelvic inflammatory disease, Life, Education, Workplace, Absenteeism, Dysmenorrhea, Statistics, Innovation, Multimedia, Cycle, Interface (computing), Meigs's syndrome, Roivant Sciences, Uterine fibroid, Fibroid, Menstrual cycle, Diagnosis, Entrepreneurship, Ageing, Uterine cancer, Primary ovarian insufficiency, Ovarian cancer, Environment, Female, Nursing, Management, Medical device, Medical imaging, Birth control, Evidence-based policy

Today, as part of National Women’s Health Week, Evidation and Myovant Sciences Ltd. (“Myovant”), a wholly owned subsidiary of Sumitovant Biopharma Ltd. (“Sumitovant”) announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.

Key Points: 
  • Today, as part of National Women’s Health Week, Evidation and Myovant Sciences Ltd. (“Myovant”), a wholly owned subsidiary of Sumitovant Biopharma Ltd. (“Sumitovant”) announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.
  • View the full release here: https://www.businesswire.com/news/home/20230517005194/en/
    “At Myovant, we know that stigma can often keep people quiet about periods, leading to delayed care and increased discomfort.
  • It also contributes to the lack of awareness about how conditions such as endometriosis and uterine fibroids can increase absenteeism and impact performance at work and school,” said Kalahn Taylor-Clark, vice president and head of Strategic Partnerships and Innovation at Myovant Sciences.
  • The survey covered four areas, including demographics, menstrual history and health, experiences at work or school, and experiences with medical providers.

Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated, Orally Delivered Chlamydia Vaccine

Retrieved on: 
Wednesday, April 12, 2023
Vaccine, Pelvic inflammatory disease, Drug development, University of Texas System, Gastrointestinal tract, University of Texas Health Science Center at San Antonio, Infection, Water, BWV, Woman, Infertility, CDC, STI, University, NHP, WHO, Disease, Safety, Pharmaceutical industry, Chlamydia

CINCINNATI, April 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the signing of a Sponsored Research Agreement (the “Agreement”) with The University of Texas Health Science Center at San Antonio (“UT Health Science Center San Antonio”) to fund a non-human primate (“NHP”) study to evaluate the efficacy of BWV-401, a live attenuated, orally delivered Chlamydia vaccine.

Key Points: 
  • CINCINNATI, April 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the signing of a Sponsored Research Agreement (the “Agreement”) with The University of Texas Health Science Center at San Antonio (“UT Health Science Center San Antonio”) to fund a non-human primate (“NHP”) study to evaluate the efficacy of BWV-401, a live attenuated, orally delivered Chlamydia vaccine.
  • In November 2022, BWV signed an exclusive, global license agreement with UT Health Science Center San Antonio for the development of this novel vaccine candidate, BWV-401, to prevent Chlamydia infection.
  • “We are thrilled to initiate this study with our partners at UT Health Science Center San Antonio for BWV-401,” said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines.
  • If undetected or left untreated, Chlamydia represents a major cause of pelvic inflammatory disease and infertility in women.

Visby Medical™ Receives FDA Clearance and CLIA Waiver for Second Generation Sexual Health Test for Women

Retrieved on: 
Tuesday, March 14, 2023
SAN, Pharmacy, Patient, Korea Disease Control and Prevention Agency, Food, Visby, STI, Associate, Neisseria gonorrhoeae, PCR, Gonorrhea, Trichomonas vaginalis, Risk, Prevention, Polymerase chain reaction, Woman, Workflow, Education, Health, Chlamydia trachomatis, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Diagnosis, CLIA, POC, Stanford University, Pelvic inflammatory disease, Pharmaceutical industry, Birth control, Operation, Medicine, Neisseria, Trichomonas, Chlamydia

The Visby Medical Sexual Health test is a fast, polymerase chain reaction (PCR) diagnostic test for the detection of sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in women.

Key Points: 
  • The Visby Medical Sexual Health test is a fast, polymerase chain reaction (PCR) diagnostic test for the detection of sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in women.
  • The CLIA-waived, Sexual Health POC test provides accurate results in under 30 minutes, enabling clinicians to test, talk and accurately treat with confidence in a single patient visit.
  • "The Visby Sexual Health Test has been a game changer for us.
  • The Visby test is a win-win, helping fight antibiotic resistance as well as the spread of untreated infection, while empowering patients to engage health services with greater confidence."

Global Infertility Drugs Market Report 2022: Factors Increasing Infertility Cases in Men and Women Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 25, 2023
Health, Pharmaceutical, Online, NICHD, Human services, Office of Inspector General, U.S. Department of Health and Human Services, Estrogen receptor, Online pharmacy, Hypogonadism, Cyst, Social stigma, Pharmacy, Cystic fibrosis, NIH, Bangladesh Technical Education Board, SERM, Obesity, Human development, Patient, Clomifene, Ovulation, PID, Diabetes, Smoking, Research, Bureau of Medical Services (U.S. Department of State), Infertility, Female, Dopamine, Menotropin, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Pelvic inflammatory disease, Letrozole, Prevalence, Hospital pharmacy, Endometriosis, Enzyme inhibitor, Men and Women, Urinary tract infection, Birth control, Woman, Gonadotropin

The Global Infertility Drugs Market size is expected to reach $4.8 billion by 2028, rising at a market growth of 6.2 % CAGR during the forecast period.

Key Points: 
  • The Global Infertility Drugs Market size is expected to reach $4.8 billion by 2028, rising at a market growth of 6.2 % CAGR during the forecast period.
  • The growing prevalence of infertility or the difficulty of bringing a baby to term throughout the world is what fuels the market for infertility medications.
  • Based on end-user, the infertility drugs Market is divided into Men and Women.
  • Based on distribution channel, the Infertility Drugs Market is divided into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy.

Global Infertility Drugs Market Report 2022: Sector to Reach $4.8 Billion by 2028 at a 6.2% CAGR

Retrieved on: 
Thursday, January 26, 2023
Online, Endometriosis, Hospital pharmacy, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Infertility, Female, Letrozole, Bangladesh Technical Education Board, Cyst, Ovulation, Office of Inspector General, U.S. Department of Health and Human Services, SERM, Pharmacy, Obesity, Pelvic inflammatory disease, Hypogonadism, Dopamine, Human services, PID, Urinary tract infection, Estrogen receptor, Smoking, Diabetes, Menotropin, Prevalence, NIH, Clomifene, Cystic fibrosis, Enzyme inhibitor, NICHD, Patient, Men and Women, Social stigma, Bureau of Medical Services (U.S. Department of State), Online pharmacy, Human development, Research, Birth control, Gonadotropin, Woman

The Global Infertility Drugs Market size is expected to reach $4.8 billion by 2028, rising at a market growth of 6.2 % CAGR during the forecast period.

Key Points: 
  • The Global Infertility Drugs Market size is expected to reach $4.8 billion by 2028, rising at a market growth of 6.2 % CAGR during the forecast period.
  • The growing prevalence of infertility or the difficulty of bringing a baby to term throughout the world is what fuels the market for infertility medications.
  • Based on distribution channel, the Infertility Drugs Market is divided into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy.
  • Based on drug class, the infertility drugs market is classified into Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, and Others.